| Literature DB >> 31015507 |
Ling-Zhi Li1, Yao Hu1,2, Shuang-Lan Ai1, Lu Cheng1, Jing Liu1, Emily Morris3, Yi Li3, Shen-Ju Gou4, Ping Fu1.
Abstract
Abnormalities of thyroid function are common in patients with nephrotic syndrome (NS). However, a limited number of studies have reported on the association between clinicopathologic features and thyroid dysfunction in patients with NS. We retrospectively studied 317 patients who had been definitively diagnosed with NS. The NS patients with thyroid dysfunction showed higher urine protein, creatinine and lipid levels and lower albumin and hemoglobin than those with normal thyroid function, with no significant differences of pathological types. After dividing thyroid dysfunction groups into five subgroups, interestingly, membranous nephropathy was the most common pathologic type, both in normal thyroid group and in subclinical hypothyroidism group (40.4% and 46.7%, respectively), followed by minimal change disease (28.1% and 21.7%, respectively); while in the hypothyroid, low T3, and low T3T4 groups minimal change disease is now the leading type (48.8%, 33.3% and 38.6%, respectively). High levels of urinary protein, creatinine, cholesterol, and platelets were independent risk factors predicting thyroid dysfunction, while higher albumin and hemoglobin were protective factors. We demonstrated that the type of renal pathology was different among NS patients in different thyroid dysfunction subgroups. Interpretation of the interactions between thyroid and renal function is a challenge for clinicians involved in the treatment of patients with NS.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31015507 PMCID: PMC6478922 DOI: 10.1038/s41598-019-42905-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Comparisons of clinical features and laboratory findings between the normal thyroid group and the thyroid dysfunction group.
| Normal thyroid | Thyroid dysfunction | P | |
|---|---|---|---|
|
| |||
| Age (Year) | 41.3 ± 14.33 | 40.65 ± 16.16 | 0.779 |
| Male (%) | 31(54.40%) | 139(53.60%) | 0.517 |
| Duration of NS (Month) | 3.00 [1.00, 8.00] | 6.00 [1.00, 10.00] | 0.098 |
| HB (g/L) | 143.14 ± 23.55 | 132.24 ± 25.17 | 0.003 |
| WBC (109/L) | 7.36 ± 2.53 | 8.02 ± 3.41 | 0.099 |
| PLT (109/L) | 202.23 ± 72.02 | 232.79 ± 86.77 | 0.014 |
| UA (umol/L) | 354.36 ± 87.87 | 361.52 ± 102.29 | 0.637 |
| PRO (g/24 h) | 4.03 ± 2.45 | 8.27 ± 6.56 | <0.001 |
| PCR (g/mmol Cr) | 0.47 ± 0.4 | 0.9 ± 0.6 | <0.001 |
| ALB (g/L) | 28.68 ± 6.19 | 22.08 ± 5.88 | <0.001 |
| SCR (umol/L) | 55.00 [61.00, 75.5] | 70.00 [55.00, 104.95] | 0.027 |
| TG (mmol/L) | 2.03 ± 1.06 | 2.46 ± 1.6 | 0.055 |
| TC (mmol/L) | 7.15 ± 2.24 | 8.48 ± 3.23 | <0.001 |
| LDL (mmol/L) | 4.54 ± 1.93 | 5.54 ± 2.78 | 0.002 |
| FT3 (pmol/L) | 4.49 ± 0.64 | 3.17 ± 1.39 | <0.001 |
| TT3 (nmol/L) | 1.64 ± 0.26 | 1.2 ± 0.43 | <0.001 |
| FT4 (pmol/L) | 15.8 ± 2.18 | 12.81 ± 3.42 | <0.001 |
| TT4 (nmol/L) | 87.32 ± 12.8 | 66.07 ± 25.38 | <0.001 |
| TSH (mU/L) | 4.57 [2.60, 6.81] | 3.00 [2.02, 3.60] | <0.001 |
| RT3 (nmol/L) | 0.36 ± 0.14 | 0.3 ± 0.15 | 0.215 |
| Hypertension | 17.50% | 20.20% | 0.653 |
| Diabetes | 1.80% | 5.70% | 0.365 |
| Pulmonary infection | 7.00% | 15.20% | 0.157 |
| AKI | 1.80% | 4.20% | 0.624 |
| CKD | 1.80% | 8.00% | 0.163 |
| MN | 40.4% | 30.7% | 0.339 |
| MCD | 28.1% | 36.2% | |
| IgAN | 10.5% | 7.8% | |
| MPGN | 3.5% | 1.9% | |
| MsPGN | 0.00% | 3.50% | |
| FSGS | 3.5% | 3.5% | |
| Secondary NS | 14.0% | 16.3% | |
Data are expressed as mean ± standard deviation, median and interquartile range, or percent frequency, as appropriate.
MN membranous nephropathy, MCD minimal-change disease, FSGS focal segmental glomerulosclerosis, MPGN membrane proliferative glomerulonephritis, MsPGN mesangial proliferative glomerulonephritis, secondary NS secondary reasons of nephrotic syndrome.
Comparisons of clinical features and laboratory findings by different thyroid dysfunction identification.
| Normal Thyroid | Subclinical hypothyroidism | Hypothyroidism | Euthyroid sick syndrome | P | |||
|---|---|---|---|---|---|---|---|
| Low T3 | Low T4 | Low T3T4 | |||||
|
| |||||||
| N | 57 | 61 | 83 | 66 | 5 | 45 | — |
| Age (Year) | 41.3 ± 14.33 | 41.72 ± 15.44 | 38.24 ± 16.79 | 42.92 ± 15.9 | 41.4 ± 16.3 | 40.33 ± 16.65 | 0.604 |
| Male (%) | 54.4% | 62.3% | 49.4% | 50.0% | 60.0% | 53.3% | 0.714 |
| Duration of NS (Month) | 6.00 [1.00, 10.00] | 4.00 [1.00, 7.00] | 2.00 [1.00, 8.00] | 3.00 [1.00, 8.00] | 3.00 [2.00, 6.00] | 2.00 [1.00, 7.75] | 0.210 |
| PRO (g/24 h) | 4.03 ± 2.45 | 6.51 ± 4.33 | 9.71 ± 7.42* | 6.71 ± 4.9 | 7.26 ± 5.22 | 10.85 ± 8.62* | <0.001 |
| PCR (g/mmol Cr) | 0.47 ± 0.4 | 0.79 ± 0.51 | 1.01 ± 0.58* | 0.76 ± 0.53 | 0.76 ± 0.37 | 1.02 ± 0.8* | <0.001 |
| ALB (g/L) | 28.68 ± 6.19 | 24.19 ± 5.65* | 19.01 ± 4.56* | 25.52 ± 6.11* | 22.88 ± 4.96 | 19.48 ± 3.99* | <0.001 |
| SCR (umol/L) | 61.50 [55.00, 75.00] | 68.00 [56.00, 84.30] | 69.00 [53.00, 94.70] | 73.80 [52.60, 119.00]* | 54.00 [53.00, 67.00] | 79.90 [59.35, 138.30]* | <0.001 |
| TG (mmol/L) | 354.36 ± 87.87 | 366.4 ± 101.97 | 343.16 ± 81.35 | 372.28 ± 123.63 | 346.66 ± 97.66 | 373.26 ± 105.08 | 0.525 |
| TC (mmol/L) | 2.03 ± 1.06 | 2.5 ± 1.51 | 2.53 ± 1.8 | 2.14 ± 1.18 | 1.83 ± 0.63 | 2.83 ± 1.88* | 0.062 |
| LDL (mmol/L) | 7.15 ± 2.24 | 8.14 ± 2.96 | 9.37 ± 3.11 | 7.19 ± 2.98* | 6.86 ± 1.84 | 9.44 ± 3.66* | <0.001 |
| FT3 (pmol/L) | 4.54 ± 1.93 | 5.3 ± 2.5 | 6.27 ± 2.69* | 4.44 ± 2.41 | 4.33 ± 1.2 | 6.31 ± 3.38* | <0.001 |
| TT3 (nmol/L) | 4.49 ± 0.64 | 4.31 ± 1 | 2.76 ± 0.71* | 3.11 ± 1.9* | 3.95 ± 0.47 | 2.28 ± 0.89* | <0.001 |
| FT4 (pmol/L) | 1.64 ± 0.26 | 1.61 ± 0.43 | 1.08 ± 0.27 | 1.14 ± 0.35 | 2.04 ± 0.2 | 0.93 ± 0.36 | <0.001 |
| TT4 (nmol/L) | 15.8 ± 2.18 | 14.7 ± 3.02 | 11.05 ± 2.68* | 14.61 ± 2.32* | 10.74 ± 1.07* | 10.34 ± 1.42* | <0.001 |
| TSH (mU/L) | 87.32 ± 12.8 | 84.87 ± 19.35 | 49.72 ± 16.71 | 86.53 ± 24.48 | 83.51 ± 1.2 | 48.85 ± 9.67 | <0.001 |
| RT3 (nmol/L) | 2.98 [2.05, 3.60] | 6.25 [5.1, 7.16] | 6.98 [5.54, 9.04] | 2.6 [1.50, 3.15] | 3.23 [2.00, 3.27] | 2.45 [1.67, 3.09] | <0.001 |
| PRO(g/24 h) | 0.36 ± 0.14 | 0.33 ± 0.12 | 0.25 ± 0.15 | 0.32 ± 0.11 | 0.28 ± 0 | 0.36 ± 0.16 | 0.214 |
| HB (g/L) | 143.14 ± 23.55 | 134.44 ± 26.16 | 135.7 ± 22.89 | 123.95 ± 26.87* | 134.6 ± 11.44 | 133.8 ± 24.84 | 0.002 |
| WBC (10^9/L) | 7.36 ± 2.53 | 7.87 ± 2.92 | 7.47 ± 2.66 | 8.12 ± 3.72 | 6.19 ± 3 | 9.13 ± 4.25* | 0.045 |
| PLT (10^9/L) | 202.23 ± 72.02 | 237.98 ± 97.93 | 241.43 ± 76.58* | 213.26 ± 90.17 | 214.6 ± 29.06 | 241.98 ± 88.11 | 0.043 |
| Hypertension | 17.5% | 26.2% | 10.8% | 27.3% | 20.0% | 17.8% | 0.120 |
| Diabetes | 1.8% | 6.6% | 1.2% | 10.6% | 0.0% | 6.7% | 0.086 |
| Pulmonary infection | 7.0% | 6.6% | 16.9%* | 15.2%* | 0.0% | 24.4%* | 0.040 |
| AKI | 1.8% | 0.0% | 4.8% | 4.5% | 0.0% | 8.9% | 0.127 |
| CKD | 1.8% | 4.9% | 3.6% | 12.1% | 0.0% | 13.3% | 0.058 |
| MCD | 28.1% | 21.7% | 48.8% | 33.3% | 20.0% | 38.6% | <0.001 |
| MPGN | 3.5% | 1.7% | 1.2% | 0.0% | 0.0% | 6.8% | |
| MsPGN | 0.0% | 1.7% | 2.4% | 4.8% | 0.0% | 6.8% | |
| MN | 40.4% | 46.7% | 22.0% | 23.8% | 0.0% | 27.3% | |
| FSGS | 3.5% | 5.0% | 1.2% | 3.2% | 80.0% | 6.8% | |
| IgAN | 10.5% | 10.0% | 6.1% | 11.1% | 0.0% | 4.5% | |
| Secondary NS | 10.9% | 11.3% | 14.9% | 22.0% | 0.0% | 8.6% | |
Data are expressed as mean ± standard deviation, median and interquartile range, or percent frequency, as appropriate.
MN membranous nephropathy, MCD minimal-change disease, FSGS focal segmental glomerulosclerosis, MPGN membrane proliferative glomerulonephritis, MsPGN mesangial proliferative glomerulonephritis, secondary secondary reasons of nephrotic syndrome.
*P < 0.05, Comparison versus normal thyroid group.
Thyroid function according to different pathologic classifications.
| MCD | MPGN | MsPGN | MN | FSGS | IgAN | Secondary | P# | |
|---|---|---|---|---|---|---|---|---|
| N | 110 | 7 | 9 | 98 | 15 | 27 | 51 | — |
| Age (Year) | 34.29 ± 16.17 | 38.86 ± 8.88 | 40.89 ± 15.09 | 47.85 ± 13.69* | 41.64 ± 17.48 | 38.04 ± 15.31 | 42.8 ± 14.88 | <0.001 |
| Male (%) | 55.5% | 71.4% | 33.3% | 55.2% | 45.5% | 34.6% | 60.8% | 0.250 |
| FT3 (pmol/L) | 3.09 ± 1.06 | 3.07 ± 0.91 | 2.95 ± 0.97 | 3.91 ± 1.75* | 3.66 ± 1.63 | 3.36 ± 1.17 | 3.24 ± 1.02 | 0.001 |
| TT3 (nmol/L) | 1.16 ± 0.49 | 0.53 ± 0.1 | 1.09 ± 0.39 | 1.49 ± 0.43* | 1.27 ± 0.1 | 1.31 ± 0.17 | 1.45 ± 0.41 | 0.058 |
| FT4 (pmol/L) | 12.68 ± 3.22 | 12.92 ± 2.25 | 13.47 ± 4 | 13.68 ± 3.53* | 14.51 ± 4.55 | 14.09 ± 3.67 | 13.59 ± 3.34 | 0.256 |
| TT4 (nmol/L) | 59.33 ± 21.24 | 44.61 ± 0.3 | 78.79 ± 22.78* | 73.99 ± 22.61* | 106.5 ± 0.2* | 91.09 ± 14.05* | 79.85 ± 29.38* | 0.014 |
| TSH (mU/L) | 5.42 ± 5.29 | 3.31 ± 1.64 | 3.7 ± 2.59 | 4.36 ± 2.81 | 4.33 ± 3.44 | 5.38 ± 3.94 | 6.45 ± 13.63 | 0.571 |
| RT3 (nmol/L) | 0.27 ± 0.13 | 0.33 ± 0.1 | 0.43 ± 0.06 | 0.35 ± 0.19 | 0.29 ± 0.15 | 0.3 ± 0.1 | 0.3 ± 0.15 | 0.403 |
| Thyroid subgroups | 0.028 | |||||||
| Normal Thyroid (%) | 14.81% | 28.57% | 0.00% | 23.00% | 18.18% | 23.08% | 16.00% | |
| Subclinical Hypothyroidism (%) | 12.04% | 14.29% | 11.11% | 28.00% | 27.27% | 23.08% | 16.00% | |
| Hypothyroidism (%) | 37.04% | 14.29% | 22.22% | 18.00% | 9.09% | 19.23% | 30.00% | |
| Low T3 (%) | 19.44% | 0.00% | 33.33% | 15.00% | 18.18% | 26.92% | 30.00% | |
| Low T4 (%) | 0.93% | 0.00% | 0.00% | 4.00% | 0.00% | 0.00% | 0.00% | |
| Low T3T4 (%) | 15.74% | 42.86% | 33.33% | 12.00% | 27.27% | 7.69% | 8.00% |
Data are expressed as mean ± standard deviation (SD), median and interquartile range (IQR), or percent frequency, as appropriate.
MN membranous nephropathy, MCD minimal-change disease, FSGS focal segmental glomerulosclerosis, MPGN membrane proliferative glomerulonephritis, MsPGN mesangial proliferative glomerulonephritis, secondary secondary reasons of nephrotic syndrome.
#Comparison among groups. *P < 0.05, Comparison versus MCD group.
Multiple regression model of variables predicting thyroid dysfunction in NS patients.
| B | SE | OR | 95% CI | P | |
|---|---|---|---|---|---|
| Sex (Male/female) | −0.233 | 0.469 | 0.792 | 0.32–1.99 | 0.619 |
| Age (Year) | −0.017 | 0.013 | 0.983 | 0.958–1.008 | 0.181 |
| Hypertension | 0.298 | 0.511 | 1.347 | 0.5–3.67 | 0.560 |
| Diabetes | 2.086 | 1.372 | 8.056 | 0.55–118.55 | 0.128 |
| Pneumonia | 0.692 | 0.781 | 1.997 | 0.43–9.22 | 0.375 |
| PRO (g/24 h) | 0.128 | 0.056 | 1.137 | 1.02–1.27 | 0.021 |
| ALB (g/L) | −0.149 | 0.038 | 0.862 | 0.8–0.93 | 0.000 |
| SCR (umol/L) | 0.012 | 0.006 | 1.013 | 1–1.03 | 0.050 |
| TC (mmol/L) | 0.611 | 0.252 | 1.843 | 1.12–3.02 | 0.015 |
| HB (g/L) | −0.018 | 0.008 | 0.983 | 0.97–1 | 0.022 |
| PLT (109/L) | 0.006 | 0.003 | 1.006 | 1–1.01 | 0.020 |
| WBC (109/L) | 0.088 | 0.077 | 1.092 | 0.94–1.27 | 0.250 |
| Pathological types | 0.052 | 0.475 | 1.053 | 0.42–2.67 | 0.913 |
PRO 24 h urinary protein, ALB albumin, SCR serum creatinine, TC total cholesterol, HB hemoglobin, WBC white blood cell count, PLT platelet.